2
Registered trials
0
Recruiting
2
Unique sponsors
2
Unique IMPs
2
Commercial trials
Drug classes (ATC)
N
Neurology/Psychiatry (ATC N)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Phase II:
2
Phase II
2 trials-
EndedDr. Willmar Schwabe GmbH & Co. KG CommercialREFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
-
EndedRecognify Life Sciences Inc. Commercial(2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YLPROPAN-1-ONE (2R,3R)-2,3-DIHYDROXYBUTANEDIOIC ACID
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Dr. Willmar Schwabe GmbH & Co. KG | Commercial | 1 | Phase II | 0 |
| Recognify Life Sciences Inc. | Commercial | 1 | Phase II | 0 |
New trials by year
2024
1
2025
1